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Abstract: Currently, the majority of neonates born to organ recipient mothers on chronic
immunosuppressive therapy are formula fed. However, over the past few years, evidence has
grown, suggesting that breastfeeding might be possible and beneficial. We designed a study assessing
the transfer of tacrolimus into the colostrum of posttransplant mothers. We assessed the amount
of tacrolimus and its metabolites, M-1 and M-3, that would be ingested by the breastfed neonates.
Concentrations of tacrolimus and its metabolites were measured in colostrum from 14 posttransplant
mothers as well as in venous cord blood and venous blood of the neonates. Test material analysis
was performed by liquid chromatography coupled with mass spectrometry (LC/MS). The amount
of ingested formula was registered, which allowed for estimation of the amount of tacrolimus and
its metabolites that would be ingested by breastfed infants. The mean amount of tacrolimus that
would be ingested by the neonates in maternal milk was 151.4 ng/kg/24 h (standard deviation
SD ± 74.39); metabolite M-1: 23.80 ng/kg/24 h (SD ± 14.53); and metabolite M-3: 13.25 ng/kg/24 h
(SD ± 9.05). The peak level of tacrolimus and metabolite M-1 in colostrum was noted 8 h after an
oral dose (3.219 ng/mL SD ± 2.22 and 0.56 ng/mL SD ± 0.60, respectively) and metabolite M-3 after
6 h (0.29 ng/mL SD ± 0.22). Low concentrations of tacrolimus and its metabolites, M-1 and M-3,
in colostrum show that neonates will ingest trace amounts of the drug. Further studies are required
to fully assess the safety of breastfeeding by posttransplant mothers.
Keywords: transplantation; breastfeeding; HPLC; drug safety; drug metabolism
1. Introduction
The pregnancy and delivery by an organ recipient mother is a high-risk one. The effect of the
chronic immunosuppressant drugs used during pregnancy on the developing organs of fetuses and
their effect on their future life remains unclear, and the literature reports are still scarce. The same
applies to the effect of potential breastfeeding. Breastfeeding is a perfectly adapted manner of
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supplying nutrition to the infant and is essential to the achievement of optimal child health. Mother’s
milk transmits elements of microbiome and immune responses and provides specific probiotics and
prebiotics that support growth of beneficial bacteria. Evidence also exists that multipotential stem
cells are secreted into breast milk and can persist within infants [1–4]. According to the American
Academy of Pediatrics, breast milk is the superior form of nutrition for an infant through the
first 12 months, especially for preterm and low-birth-weight (LBW) infants. New findings show
that breastfeeding is potentially one of the top interventions for reducing mortality in preterm
infants [5–7]. Neonatal outcomes reported in transplant recipients show a high incidence of preterm
and low-birth-weight infants; more than 50% of babies born to organ transplant recipients are
premature. Because breastfeeding is particularly beneficial for preterm infants, it would be an
advantage for that population [1,2,8–12]. In the past, mothers on chronic immunosuppressive therapy
(tacrolimus or cyclosporine) were advised against breastfeeding [5–7,13]. It is known that, after oral
administration, tacrolimus reaches its peak blood levels after about 1 to 3 h, and the drug is excreted
into breast milk. Therefore, according to the summary of product characteristics, its harmful effects
on the newborn cannot be ruled out, and women receiving tacrolimus should not breastfeed [14].
In recent years, however, few reports emerged confirming the presence of tacrolimus in trace levels in
the mother’s milk. Therefore, some authors and current guidelines of scientific societies suggest that
this policy might be changed. Therefore, we designed the study aiming to assess the concentration
of tacrolimus and its M-1 and M-3 metabolites in the colostrum of the post-transplant mothers and
the peak level in relation to the time elapsed from the last dose of medication; to assess the amount of
tacrolimus and its M-1 and M-3 metabolites that would be ingested by the neonates whose mothers
would choose to breastfeed; and to assess the mean concentration of tacrolimus and its metabolites in
cord blood and in the venous blood of the newborns.
2. Materials and Methods
The study group consisted of 14 graft recipients on tacrolimus therapy (including 13 after liver
and 1 after kidney transplantation) and their neonates born in the First Department of Obstetrics and
Gynecology, Medical University of Warsaw, between 2012 and 2015. All the mothers enrolled in the
study signed an informed consent form. The study was approved by the Institutional Review Board
(KB/195/2012). During pregnancy and after delivery, the tacrolimus concentrations in the mothers’
blood was measured, and the bi-daily dose of drug was titrated according to blood concentration to
maintain a therapeutic level of 5–10 ng/mL. Preterm delivery between 30 and 36 weeks of pregnancy
was observed in 64.3% of cases, and 50% of the newborns had a low birth weight of <2500 g.
The selected details on the characteristics of the study group are shown in Table 1.
Samples were collected as follows: colostrum from the mother (70 samples), umbilical venous cord
blood (14 samples), and venous blood of the newborn (14 samples). Colostrum samples were collected
from the mothers who agreed to sustain lactation and were not administered lactation-suppressing drugs
after the delivery. Every mother delivered five samples of colostrum in the amount of two milliliters
each into sterile test tubes. Colostrum was expressed manually by the mothers according to a schedule
in consecutive time points: 1t before the dose (directly before the next dose of immunosuppressant);
2t 2 h after the dose; 3t 4 h after the dose; 4t 6 h after the dose; and 5t 8 h after the dose. None of
the mothers decided to breastfeed their infant and, after the sample collection, the mothers received
lactation-suppressing drugs. All the newborn babies were fed with formula after the delivery. On the day
of sample collection, the amount of formula ingested by every newborn was also registered. We assumed
that it was equal to the amount of colostrum that a breast-fed neonate would ingest.
Three milliliters of umbilical cord blood were collected immediately after the delivery from the
umbilical vein, with a sterile needle and syringe, into a sterile Ethylene-Diamine-Tetra-Acetic Acid (EDTA)
test tube. One milliliter of the newborn’s venous blood was collected with a sterile needle and syringe into
a sterile EDTA test tube on the first day of life, together with other routine blood tests that were performed.
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Table 1. Selected details on study group characteristics.
Patient No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Years from transplant 9 3 3 11 6 13 5 2 5 11 4 7 11 4
Liver (LT) or Kidney Graft (KT)
and underlying disease LT AIH LT Hep B LT WD LT WD LT Hep C LT WD LT AIH LT PSC KT GN LT WD LT AIH LT LT HCa LT AIH
Other diseases RCh - Ch - - DM - CU HA DM - - HA -
Mode of delivery CS VD CS CS CS CS CS CS VD CS VD VD CS CS
Weeks of pregnancy 30 36 34 38 36 39 34 39 36 34 32 39 33 38
Birth weight (g) 1320 3090 2280 3250 2900 3120 2350 3400 2400 2450 2010 4300 1870 2610
Tacrolimus dose (mg) 2 + 2 3 + 2 3 + 2 7 + 7 7 + 7 5 + 4 3 + 3 4 + 3 5 + 4 3 + 3 5 + 5 2 + 3 3 + 3 3 + 2
Other IS drugs - - AZA, P - AZA, P - P P AZA, P P P AZA, P P AZA, P
Abbreviations: LT: liver transplant, KT: kidney transplant, AIH: autoimmune hepatitis, Hep B: Hepatitis B, Hep C: hepatitis C, WD: Wilson disease, GN: glomerulonephritis,
HCa: hepatocellular carcinoma, RCh: recurrent cholangitis, Ch: cholestasis, CU: ulcerative colitis, DM: diabetes mellitus, HA: arterial hypertension, CS: cesarean section, VD: vaginal
delivery, P: prednisone, AZA: azathioprine.
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Collected samples were used to measure the concentrations of the immunosuppressive drug
tacrolimus and its metabolites 13-O-desmethyl tacrolimus (M-1) and 15-O-desmethyl tacrolimus (M-3).
Metabolite 31-O-desmethyl Tacrolimus (M-2) levels were undetectable in our material.
Test material: Samples were deep frozen and transported to the Institute of Biochemistry and
Biophysics of the Polish Academy of Sciences. Materials were secured and stored until the time of
analysis in the low-temperature freezer (−80 ◦C) in the Laboratory of Mass Spectrometry, Drug and
Metabolites Analysis Division.
Chemicals: Ascomycin and tacrolimus were acquired from Toronto Research Chemicals, Inc.
(North York, ON, Canada). 13-O-desmethyl tacrolimus (M-1) and 31-O-desmethyl tacrolimus
(M-2) were kindly provided by Astellas Pharma (Osaka, Japan). All stock solutions were
prepared in methanol and stored in −20 ◦C. Commercial kits 6PLUS1® Multilevel Calibrator Set
Immunosuppressants in whole blood and Chromsystems MassCheck® Immunosuppressants whole
blood control was obtained from Chromsystems Instruments & Chemicals GmbH (Munich, Germany).
Liquid chromatography coupled with mass spectrometry (LC-MS) grade methanol, high performance
liquid chromatography (HPLC) grade methanol, HPLC grade acetonitrile, methyl-tert-butyl ether,
and formic acid were purchased from J.T. Baker. Zinc sulfate monohydrate was purchased from
Sigma-Aldrich (St. Louis, MO, USA), and analytical grade ammonium acetate was obtained from
POCH (Gliwice, Poland). Ultra-pure water was produced by a water purification system (Milli-Q,
Millipore, Milford, MA, USA).
Sample extraction procedure: Whole blood samples were prepared by the protocol described
before [15]. Colostrum samples were prepared by transferring 2 mL (patient samples, calibrators,
and quality control samples) to a 9-mL test tube, and a 700 µL of 2% aqueous zinc sulfate solution
with internal standard (3 ng/mL) and 350 µL of acetonitrile were added. After brief vortexing, 3 mL
of methyl-tert-butyl ether was added to extract tacrolimus and metabolites. Samples were vortexed
for 3 min and centrifuged for 10 min at 3000 rpm. The organic portion was transferred into a clean
1.5-mL test tube and evaporated under a stream of nitrogen in a water-bath Turbo-Vap evaporator
(Caliper Life Sciences, Hopkinton, MA, USA). The residue was reconstituted in 100 µL 75% methanol
by vortexing 10 min and transferred into a chromatographic vial. The injection volume was 30 µL.
Analyses: The LC/MS method was followed as described before [16]. The concentration of
tacrolimus and its metabolites was calculated using a calibration curve derived from a series of
calibrator samples. Calibration curves for all analytes were generated by comparing the ratio
of the peak area of the analyzed compound to the peak of the internal standard against known
standard tacrolimus or metabolite concentrations. The peak area ratio of the patient sample was
compared with an obtained calibration curve. Tacrolimus concentration was determined using
calibrators from a commercially available kit, 6PLUS1® Multilevel Calibrator Set Immunosuppressants
in whole blood (Chromsystems, Munich, Germany). The calibration curve range for tacrolimus was
2.38–43.9 ng/mL. For M-1 and M-2 in-house calibration, samples were prepared by spiking standard
stock solutions in human whole blood from volunteers with a final range of 0.01–1.5 ng/mL for
both metabolites. For the determination of concentration in colostrum, own calibration standard
mix was prepared for all analytes by diluting standard stock solutions of tacrolimus and metabolites
in blank colostrum. The concentration range was 0.025–5 ng/mL for tacrolimus, 0.01–1.5 ng/mL
for M-1, and 0.005–1.5 ng/mL for M-2. Concentration of M-3 tacrolimus was quantified using an
M-1 tacrolimus calibration curve. Mean R2 coefficients of calibration curves from six calibration
samples were not lower than 0.97. To ensure control of the method for the determination of analytes in
whole blood, external control samples (Chromsystems MassCheck® Immunosuppressants whole blood
control) for tacrolimus and in-house control samples for metabolites were used. For the colostrum
procedure, control samples were prepared by adding tacrolimus and metabolites into drug-free
colostrum. The method showed good inter-assay and intra-assay precision below 10%.
Data concerning tacrolimus and its metabolite concentration in colostrum were analyzed to
estimate the amounts that would be ingested by a breast-fed infant. The AUC parameter (area under
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the curve) was found by adding the area of the trapezoids method with the use of a PK package
(ver. 1.3). For every mother, the mean concentration of tacrolimus and its metabolites in colostrum
was calculated with use of the AUC parameter in timepoints: 1t, 2t, 3t, 4t, and 5t, repeating the
measured value from t1 as a concentration after 12 h (before the next oral dose) and multiplying twice
to estimate the result after 24 h. The result was divided by 24 and multiplied by the amount of milk
that a breast-fed newborn would ingest on the day of sample collection. Thus, the amount of ingested
tacrolimus and its metabolites for every newborn was calculated in ng/24 h and then recalculated by
the dose, based on kg of bodyweight per 24 h.
All statistical analyses were performed by the R Project for statistical computing (version 3.3.2,
R Foundation for Statistical Computing, Vienna, Austria). In the statistical analysis, the comparison of
two independent samples was performed by a Mann–Whitney nonparametric test. The nonparametric
test was used because the distribution of analyzed variables was not normal, which was confirmed by
means of a Shapiro–Wilk test. The results in time were compared using the ANOVA Friedman test,
which is a nonparametric counterpart of the analysis of variance for repeated measurements. A p value
≤ 0.05 was considered statistically significant.
3. Results
The concentrations of tacrolimus and its metabolites, M-1 and M-3, were measured in colostrum
collected in time points 1t, 2t, 3t, 4t, and 5t (Figure 1).
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Figure 1. The mean concentrations of tacrolimus (TAC) and its M-1 and M-3 metabolites in colostrum
collected at consecutive timepoints (1t, 2t, 3t, 4t, 5t).
The highest concentration of tacroli us in colostru was observed after 8 h fro oral dose and
was equal t . L SD ± .218. Similarly, 8 h after drug intake, the mean co centration of
M-1 metabolite reached peak level equal to 0.56 ng/mL SD ± 0.60. -3 et lite c ce tr ti in
colostru s i est fter fro drug intake by the mother and was 0.29 ng/mL SD ± 0.218.
The lowest mean co centrations of tacrolimus and its M-1 and M-3 metabolites were noted just before
the next dose of drug and were for tacrolimus 2.351 ng/mL SD ± 1.44, for M-1 metabolite 0.34 ng/mL
SD ± .250, and 0.19 ng/mL SD ± 0.16 for M-3 metabolite.
o statistical difference as revealed hen the concentrations of tacroli us a its et lites,
-1 a - , i c l str i consecutive time points were analyzed (chi2; p = 0.099, p = 0.305,
p = 0.729, respectively).
The amount of formula ingested by the newborns on the day of colostrum collection and estimated
amounts of tacrolimus and its metabolites, M-1 and M-3, ingested with colostrum converted int dose
by kilogram of body weight per 24 h are presented in Table 2.
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Table 2. Characteristics of neonates and amounts of tacrolimus and its metabolites potentially ingested with breastmilk.





















1 30 1320 4 70 68.979 52.257 29.342 22.229 1.517 1.149
2 36 3090 2 160 304.013 98.386 71.453 23.124 18.453 5.972
3 34 2280 2 110 242.284 106.265 59.904 26.274 12.247 5.371
4 38 3250 3 240 532.74 163.92 72.86 22.418 27.56 8.48
5 36 2900 2 140 366.333 126.322 90.615 31.247 27.067 9.333
6 39 3120 2 160 385.907 123.688 89.4 28.654 37.733 12.094
7 34 2350 2 140 614.798 261.616 42.782 18.205 56.058 23.855
8 39 3400 2 160 347.12 102.094 52.027 15.302 32.507 9.561
9 36 2400 2 140 564.912 235.38 28.105 11.71 79.998 33.333
10 34 2450 2 120 241.84 98.71 25.23 10.298 20.89 8.527
11 32 2010 2 120 186.35 92.711 42.52 21.154 28.61 14.234
12 39 4300 2 180 1348.89 313.695 296.4 68.93 116.775 27.157
13 33 1870 3 120 288.8 154.439 19.53 10.444 19.04 10.182
14 38 2610 3 200 496.2 190.115 60.717 23.263 42.267 16.194
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In our group, the mean dose of tacrolimus that would be ingested by the breast-fed infants was
151.4 ng/kg/24 h (SD ± 74.39). The doses of metabolites were 23.80 ng/kg/24 h (SD ± 14.53) for M-1
and 13.25 ng/kg/24 h (SD ± 9.05) for M-3 metabolite (Figure 2).
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Figure 2. Distribution of tacrolimus and its metabolites M-1 and M-3 amount that would be ingested
by breast-fed infants (ng/kg/24 h).
We estimated amounts of tacrolimus and its metabolites (in ng/kg/24 h) that would be ingested
by LBW infants in comparison to those born with body weight above 2500 g. Mean dose of tacrolimus
and M-3 metabolite that would be ingested by LBW newborns would be similar to that by newborns
weighing > 2500 g (for tacrolimus: 143.05 ng/kg/24 h (SD± 78.33) vs. 159.75 ng/kg/24 h (SD ± 75.44);
p value = 0.54 and for M-3 metabolite: 13.81 ng/kg/24 h (SD ± 11.22) versus 12.68 ng/kg/24 h
(SD ± 7.14); p value 0.12). The statistical significance was noted only in the case of M-1 metabolite.
The amount of ingested M-1 metabolite would be on average higher in babies born with body weight
above 2500 g in comparison to LBW infants (30.42 ng/kg/24 h (SD ± 17.72) versus 17.19 ng/kg/24 h
(SD ± 6.43); p value = 0.03).
The amount of tacrolimus and its metabolites ingested by the infants born prematurely (<37 weeks
of gestation) and term infants was also subject to analysis. There was no difference in mean
values of tacrolimus and its M-3 metabolite that would be ingested by the premature infants in
comparison to those born at term (for tacrolimus 136.23 ng/kg/24 h (SD ± 69.52) vs. 178.70
(SD ± 82.87); p value = 0.24; for M-3 metabolite 12.44 ng/kg/24 h (SD ± 10.12) vs. 14.697 (SD ± 7.57);
p value = 0.438). The amount of ingested M-1 metabolite would be on average higher in babies born
at term in comparison to infants born prematurely (114.28 (SD ± 102.77) vs. 45.50 (SD ± 23.93);
p value = 0.042).
The distributions of the concentrations of tacrolimus and its metabolites in venous cord blood
and in venous blood of the neonates are presented in detail in Figure 3. The mean concentration of
tacrolimus in cord blood was 5.20± 1.94 ng/mL, the M-1 metabolite was 0.41± 0.168 ng/mL, and M-3
metabolite was 0.12 ± 0.46 ng/mL. The mean concentration of tacrolimus in venous blood of the
Nutrients 2018, 10, 267 8 of 13
newborn was 3.89 ± 1.58 ng/mL, the M-1 metabolite was 0.51 ± 0.21 ng/mL, and the M-3 metabolite
was 0.20 ± 0.11 ng/mL.
Mean concentration of tacrolimus in cord blood was higher than that in venous blood of the
newborn, whereas the metabolite concentrations were higher in venous than in cord blood, but the
comparison of mean concentrations of tacrolimus and its metabolites, M-1 and M-3, in venous cord
blood and in venous blood of the newborn revealed no statistical difference.
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The correlation coefficient between mean concentration of tacrolimus and its metabolites, M-1 and
M-3, in colostrum and their concentrations in cord blood were calculated, and the analysis revealed no
statistical difference.
4. Discussion
The important aspect of our study was to estimate the amount of tacrolimus and its metabolites,
M-1 and M-3, that would be ingested by the newborns during the first days of life if the mothers
chose to breastfeed. The results show that the amounts would be very small both for tacrolimus
(0.15 µg/kg/24 h) and for its metabolites, M-1 and M-3 (0.02 and 0.01 µg/kg/24 h, respectively).
The measurement of tacrolimus and its metabolite concentration in 70 samples of colostrum collected
from 14 post-transplant mothers allowed for the acquisition of a relatively large data set and
complements limited data published in medical databases. The limitation of our study is mainly
due to the small number of participants and the fact that post-transplant mothers did not choose to
breastfeed and just sustained lactation for a few days after the delivery to collect colostrum samples for
our study. Colostrum is different from mature breast milk in its composition and volume. Therefore,
the limitation of our study is to assume the amount of excreted tacrolimus and its metabolites in
colostrum exactly equals that excreted in mature breast milk. Unfortunately, the participating mothers
did not wish to sustain lactation for longer periods of time. Therefore, designing a study that would
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assess the safety of breastfeeding in larger groups of post-transplant mothers and sustaining lactation
for a longer period of time would be very difficult in practice.
The high percentage of preterm births among posttransplant mothers (20% of kidney graft
recipients deliver before 34 weeks and 50% before 37 weeks of pregnancy and for liver recipient these
numbers reach 39% and 16% respectively) is confirmed in the recently published Annual Report of
Transplant Pregnancy Registry. Similarly, the prevalence of low birth weight (LBW) and very low birth
weight (VLBW) neonates reaches 42% and 10% in kidney graft pregnancies and 30% and 8% in mothers
after liver transplantation [17]. Therefore, in the light of published data on the risks and benefits of
breastfeeding, breastfeeding seems to be especially important in this subgroup of neonates born to
graft recipients. Early enteral milk feeding significantly reduces the risk of necrotizing enterocolitis in
LBW and preterm infants [18,19]. ESPGHAN (The European Society for Paediatric Gastroenterology
Hepatology and Nutrition) guidelines suggest that in preterm infants where no own mother’s milk is
available donor human milk should be regarded as the first alternative. Unfortunately, this intervention
is not feasible in every setting [20].
Currently, there are no standards regarding the feeding of neonates and infants by recipient
mothers. The consequences of even minimal fetal exposure to chronic immunosuppressive therapy are
unknown. However, evidence to date suggests that babies’ exposure to the drug during breastfeeding
is relatively insignificant in comparison to that in utero. Some authors suggest that women taking
tacrolimus who wish to breastfeed after appropriate counseling should not be discouraged from
doing so. However, experts say that deciding to breastfeed while continuing treatment with an
agent for which in utero exposure also has occurred is different from initiating a new therapy while
breastfeeding [21–23].
The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology
(BHPR) and the European League Against Rheumatism (EULAR) published guidelines for tacrolimus
in pregnancy and breastfeeding. According to BSR, BHPR, and EULAR, tacrolimus is compatible
throughout pregnancy and breastfeeding [24,25].
In 1997, Jain et al. analyzed the concentrations of tacrolimus in mother’s blood, colostrum,
placenta, cord blood, and baby’s blood. The authors suggested that the infants were protected from
drug toxicity in utero by a partial placental barrier. In 9 of 10 placental samples, the tacrolimus
concentration was 2 to 56 times higher than that in cord blood. Placental tacrolimus levels also usually
exceeded that of maternal plasma (median fourfold). Tacrolimus was present in all 10 breast milk
samples from six mothers at almost half the concentration as in contemporaneous maternal samples
(median ratio was 0.5). The mean tacrolimus concentration in the colostrum was 0.79 ng/mL ± 0.48.
None of the mothers chose to breastfeed [26].
In our study, the mean concentration of tacrolimus measured in 70 samples of colostrum was
four times higher. The peak level (3.23 ng/mL, SD ± 2.218) was observed after 8 h from oral dose,
and the lowest concentration (2.35 ng/mL, SD± 1.44) was noted just before the next dose of tacrolimus.
Jain et al. did not analyze the metabolite concentrations.
French et al. published a case report based on one liver recipient mother, suggesting that maternal
therapy with tacrolimus may be compatible with breastfeeding [27]. The authors reported tacrolimus
concentrations in human milk while the mother was exclusively breastfeeding the infant. The mean
concentration of tacrolimus in the milk was 0.43 ng/mL. The highest concentration of tacrolimus in
milk (0.57 ng/mL) was observed one hour after oral dose. Therefore, the tacrolimus dose that an
exclusively breast-fed infant would ingest was 0.06 µg/kg/24 h (0.43 ng/mL × 150 mL/kg/24 h),
which is 0.06% of the mother’s weight-adjusted dose (0.1 mg/kg/24 h). The maximum tacrolimus
dose the infant would receive through breastfeeding was 0.09 µg/kg/24 h, which corresponds to about
0.09% of the mother’s weight-adjusted dose.
Our study suggests that the maximal concentration of tacrolimus in colostrum was more than
5 times higher than in the study by French et al. (3.22 ng/mL versus 0.57 ng/mL) and was noted 8 h
after the oral dose.
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The case report by Gardiner et al. shows that the average tacrolimus concentration in milk
was 1.8 µg/L, and the baby ingested approximately 0.5% of the maternal dose (weight-adjusted).
The highest concentration of tacrolimus in milk (2.1 µg/L) was observed 8.5 h after the maternal
dose [28]; this finding was similar to our result.
In 2013, Bramham et al. compared tacrolimus levels in breast-fed and formula-fed infants,
which did not reveal any differences, and the blood concentrations decreased with the time elapsing
from delivery. In this study, the estimated infant dose was based on the highest breast milk
concentration [22]. Bramham et al. assumed that a neonate would drink 0.15 L/kg/24 h of breast milk;
for a neonate weighing 2.4 kg, that would be 0.36 L/24 h of breast milk. Considering that the maximal
concentration of tacrolimus in breast milk was 1.56 µg/L, it was estimated that the neonate would
ingest 0.24 µg/kg/24 h.
In our study, we precisely measured the amount of milk taken by every newborn on the day of
collection of colostrum samples and the concentration of tacrolimus in colostrum of every patient.
Our analysis indicates that the newborns would on average ingest 0.15 µg/kg/24 h of tacrolimus
with breast milk, which is less than in the study by Bramham et al., although the mean maximal
concentration of tacrolimus was higher in our study than in the above-cited study by Bramham et al.
(3.22 µg/L versus 1.56 µg/L). The difference may be explained by the fact that our patients collected
only colostrum samples, whereas in the study by Bramham et al. the breast milk samples collected
between days 1 and 72 were analyzed. Nevertheless, the authors did not observe any relationship
between breast milk concentration and number of days postpartum.
According to Bramham et al., low birth weight at delivery was significantly associated with higher
infant tacrolimus levels. Infant tacrolimus levels fell with higher birth weights; for each 500-g increase,
there was a −25% change in geometric mean tacrolimus level (95% confidence interval CI, −42% to
−1%; p = 0.034). In our study, there were no such associations. There was no difference in the average
amount of tacrolimus that infants would ingest with birthweight < 2500 g (143.05 ng/kg/24 h) and
≥2500 g (159.75 ng/kg/24 h).
In the study by Zheng et al., peak and trough concentrations in milk were 1.11 and 0.78 ng/mL,
respectively. The mean concentration of tacrolimus in milk was 0.93 ng/mL. Daily tacrolimus excretion
into milk was estimated to be 32.0 ng. The amount of tacrolimus excreted into breast milk over a 12 h,
steady-state dosing interval was determined in only one patient, treated with 1.5 mg of oral tacrolimus
twice daily. Tacrolimus concentration in breast milk peaked later than in blood or plasma [29].
The data from the National Transplantation Pregnancy Registry, encompassing the largest
case series, also show that we might be cautiously optimistic about the immunosuppressant
use in breastfeeding females. Other investigators and clinicians suggest that breastfeeding by
transplant recipient mothers remains an area in which recommendations are evolving; future research
should include studies that lead to the establishment of guidelines for dosing, the measurement of
levels of drugs, and the long-term follow-up of children breast-fed by recipients on maintenance
immunosuppressive therapy. The preliminary findings are promising [2,12,21,24,25,29–34].
5. Conclusions
Low concentrations of tacrolimus and its metabolites, M-1 (13-O-desmethyl tacrolimus) and M-3
(15-O-desmethyl-tacrolimus), in colostrum indicate that breast-fed neonates will ingest trace amounts
of drugs, thus presenting the possibility that neonates could be safely breast-fed. Our results show that
a breast-fed neonate would ingest 150 ng/kg/24 h and, assuming maternal dose being between 0.1 to
0.2 mg/kg/24 h, this means the infant’s dose would be approximately 1/1000th that of the mother’s.
According to a recently published Annual Report of Transplant Pregnancy Registry International,
there is a notable increasing trend in the number of graft recipients choosing to breastfeed, with the
number exceeding 60% of live births in 2016 [17]. It is necessary to gather more data to confirm the
safety of breastfeeding by posttransplant mothers, but the exposure through breastmilk seems to be
minimal. In light of the findings of these data, the possibility of breastfeeding by these patients
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will be an extremely important element in preventing lifestyle diseases and obesity in children
and will improve the health of the baby. Undoubtedly, the possibility of breastfeeding would
also be a very precious experience for organ transplant mothers, allowing for the full enjoyment
of motherhood, which could have a very positive impact on the struggle with their underlying disease.
The possibility of breastfeeding could indicate their full social and medical recovery after a successful
organ transplantation.
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